Published in J Cell Physiol on April 01, 2012
Transglutaminase 2 in cancer. Am J Cancer Res (2015) 0.79
Evidence in support of potential applications of lipid peroxidation products in cancer treatment. Oxid Med Cell Longev (2013) 0.78
Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov (2009) 4.16
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol (2008) 3.21
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
The vascular endothelium of the adipose tissue gives rise to both white and brown fat cells. Cell Metab (2012) 2.97
Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med (2002) 2.82
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol (2010) 2.69
Systematic review of cuff and pouch cancer in patients with ileal pelvic pouch for ulcerative colitis. Inflamm Bowel Dis (2014) 2.10
Development and validation of a practical score to predict pain after excisional hemorrhoidectomy. Int J Colorectal Dis (2014) 1.95
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol (2008) 1.91
From cell-ECM interactions to tissue engineering. J Cell Physiol (2004) 1.91
Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One (2008) 1.90
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer (2005) 1.81
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist (2006) 1.80
Leptin is induced in the ischemic cerebral cortex and exerts neuroprotection through NF-kappaB/c-Rel-dependent transcription. Stroke (2008) 1.72
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol (2009) 1.71
Leptin signaling in breast cancer: an overview. J Cell Biochem (2008) 1.71
Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist (2006) 1.70
From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J Cell Biochem (2007) 1.65
Oxidative stress effects on endothelial cells treated with different athletes' sera. Med Sci Sports Exerc (2012) 1.62
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Cell cycle regulation and neural differentiation. Oncogene (2003) 1.59
Is flexible bronchoscopy necessary to confirm the position of double-lumen tubes before thoracic surgery? Eur J Cardiothorac Surg (2011) 1.57
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist (2009) 1.53
Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle (2009) 1.50
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res (2011) 1.48
Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol (2007) 1.47
Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nat Clin Pract Cardiovasc Med (2008) 1.47
miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol (2013) 1.46
Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more? J Clin Oncol (2004) 1.46
The occurrence of acute myocardial infarction in Italy: a five-year analysis of hospital discharge records. Aging Clin Exp Res (2010) 1.44
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol (2012) 1.43
Role of GPR30 in testicular germ cell tumors: a potential new anticancer target. Cancer Biol Ther (2011) 1.43
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther (2010) 1.43
Wasting lives: the effects of toxic waste exposure on health. The case of Campania, Southern Italy. Cancer Biol Ther (2011) 1.42
Integrating role of T antigen, Rb2/p130, CTCF and BORIS in mediating non-canonical endoplasmic reticulum-dependent death pathways triggered by chronic ER stress in mouse medulloblastoma. Cell Cycle (2012) 1.41
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer (2006) 1.41
Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res (2008) 1.40
Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer (2011) 1.39
The transcriptional co-activators CBP and p300 are activated via phenylephrine through the p42/p44 MAPK cascade. J Biol Chem (2001) 1.37
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 1.36
Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J Biol Chem (2005) 1.33
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget (2012) 1.33
Activation of MyoD-dependent transcription by cdk9/cyclin T2. Oncogene (2002) 1.33
Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med (2011) 1.33
Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle (2008) 1.32
Advantages and limitations of microarray technology in human cancer. Oncogene (2003) 1.30
Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res (2008) 1.30
Smart materials as scaffolds for tissue engineering. J Cell Physiol (2005) 1.30
In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget (2013) 1.26
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer (2009) 1.24
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res (2013) 1.23
Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care (2010) 1.23
CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc Natl Acad Sci U S A (2010) 1.21
Lung Cancer: Are we up to the Challenge? Curr Genomics (2010) 1.21
Scaffold's surface geometry significantly affects human stem cell bone tissue engineering. J Cell Physiol (2008) 1.20
Inhibition of SNAP25 expression by HIV-1 Tat involves the activity of mir-128a. J Cell Physiol (2008) 1.19
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. Eur J Cancer (2011) 1.19
Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein. Oncogene (2002) 1.19
Leptin increases axonal growth cone size in developing mouse cortical neurons by convergent signals inactivating glycogen synthase kinase-3beta. J Biol Chem (2006) 1.18
pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. Oncogene (2003) 1.17
Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene (2004) 1.16
Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol (2005) 1.16
The gap between the physiological and therapeutic roles of mesenchymal stem cells. Med Res Rev (2014) 1.15
Complications and functional outcomes of restorative proctocolectomy for ulcerative colitis in the elderly. BMC Surg (2013) 1.13
CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation. J Pathol (2004) 1.11
Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J Cell Biochem (2005) 1.10
Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res (2004) 1.08
Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability. Oncogene (2003) 1.08
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget (2014) 1.07
Effects of a new pocket device for negative pressure wound therapy on surgical wounds of patients affected with Crohn's disease: a pilot trial. Surg Innov (2013) 1.06
Characterization of a novel peripheral pro-lipolytic mechanism in mice: role of VGF-derived peptide TLQP-21. Biochem J (2012) 1.06
PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. Endocrine (2014) 1.06
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle (2013) 1.06
Deacetylase recruitment by the C/H3 domain of the acetyltransferase p300. Oncogene (2004) 1.06
The tumor suppressor role of CTCF. J Cell Physiol (2012) 1.06
In vivo phenotyping of the ob/ob mouse by magnetic resonance imaging and 1H-magnetic resonance spectroscopy. Obesity (Silver Spring) (2006) 1.05
Human polyomaviruses and brain tumors. Brain Res Brain Res Rev (2005) 1.04
In vitro senescence of rat mesenchymal stem cells is accompanied by downregulation of stemness-related and DNA damage repair genes. Stem Cells Dev (2009) 1.03
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol (2014) 1.02
Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol (2007) 1.02
Cdk9 phosphorylates p53 on serine 392 independently of CKII. J Cell Physiol (2006) 1.02
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. J Cell Physiol (2014) 1.02
Sensory or sympathetic white adipose tissue denervation differentially affects depot growth and cellularity. Am J Physiol Regul Integr Comp Physiol (2004) 1.02
The retinoblastoma family: twins or distant cousins? Genome Biol (2002) 1.02
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005. J Exp Clin Cancer Res (2009) 1.02
Analysis of a mutant p53 protein arising in a medulloblastoma from a mouse transgenic for the JC virus early region. Anticancer Res (2007) 1.01
Brg1 chromatin remodeling factor is involved in cell growth arrest, apoptosis and senescence of rat mesenchymal stem cells. J Cell Sci (2007) 1.01
Reversible transdifferentiation of secretory epithelial cells into adipocytes in the mammary gland. Proc Natl Acad Sci U S A (2004) 1.01
Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer (2008) 1.01
Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol (2005) 1.00
Electrochemotherapy of cutaneous metastastes from breast cancer in elderly patients: a preliminary report. BMC Surg (2012) 0.99